Iroko Pharmaceuticals's Submicron NSAIDs Demonstrate Efficacy at Lower Doses in Studies in Patients With Acute and Chronic Pain
4/12/2013 9:47:46 AM
More...
|
Iroko Pharmaceuticals Announces Acceptance for NDA Filing of Lower Dose Submicron Diclofenac for the Treatment of Mild to Moderate Acute Pain in Adults
3/4/2013 10:40:02 AM
More...
|
Iroko Pharmaceuticals and University of Pennsylvania Launch Multi-Year Young Scientist Scholarship Program
12/12/2012 11:07:49 AM
More...
|
Philadelphia Mayor Nutter and Local Officials Celebrate Opening of Iroko Pharmaceuticals' Environmentally Friendly Global Headquarters in The Navy Yard
12/12/2012 11:07:20 AM
More...
|
Results From a Phase 3 Study Show Iroko Pharmaceuticals’s Investigational Submicron Indomethacin Provided Effective Pain Relief at Lower Doses
12/7/2012 10:12:45 AM
More...
|
Iroko Pharmaceuticals Release: Novel, Submicron Particle, Lower-Dose Diclofenac Demonstrated Relief of Acute Pain in Phase 3 Study
6/21/2012 9:49:42 AM
More...
|
Iroko Pharmaceuticals Engages SynopiaRx to Navigate Managed Care Landscape
5/23/2012 11:07:08 AM
More...
|
Iroko Pharmaceuticals Makes Strategic Additions to Executive Team with Appointment of Clarence L. Young, M.D. as Chief Medical Officer and Moji James as General Counsel
4/18/2012 10:06:14 AM
More...
|
Iroko Pharmaceuticals Release: Pain Medicines in Novel Formulations Show Potential for Relief at Lower Doses
11/7/2011 7:54:25 AM
More...
|
Phase 2 Results for Nano-formulated NSAIDs under Development at Iroko Pharmaceuticals to Be Reported at American College of Rheumatology Meeting
11/4/2011 7:38:54 AM
More...
|
|